Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer

  • Technology appraisal guidance
  • TA389
  • Published: 

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222) [ID468]: evaluation report

Table of Contents

01. NICE's response to comments on the Appraisal Consultation Document (ACD)

02. Consultee comments on the ACD - Pharma Mar

03. Consultee comments on the ACD - Ovacome

04. Consultee comments on the ACD - Royal College of Nursing

05. Consultee comments on the ACD - Royal College of Physicians and NCRI-RCR-ACP-JCCO

06. Consultee comments on the ACD - Department of Health

07.Commentator comments on the ACD - Health Improvement Scotland

08. Commentator comments on the ACD - Glaxo Smith Kline

09. Commentator comments on the ACD - BMJ-TAG

10. Public comments on the ACD received via the NICE website

11. Assessment Group Erratum

Please follow the link at the bottom of this page to download Adobe Reader if required.

 

This page was last updated: 29 December 2014